Notably, despite PD therapies focusing predominantly on inhibition of MAO-B to reduce DA breakdown and, potentially, to decrease formation of toxic DA oxidation products [77, 78], the MAO-B isoform is predominantly expressed in glial cells, while the DA breakdown in neurons occurs mainly via the MAO-A isoform [23]. Here, MAOA is linked to Parkinson disease.